Literature DB >> 2868853

Metabolism of 2-chloroethyl nitrosocarbamoylcystamine by rat liver subcellular fractions.

D Godeneche, J C Madelmont, M F Moreau, J Duprat, R Plagne, G Meyniel.   

Abstract

Previously we have shown that a new nitrosourea, 2-chloroethyl nitrosocarbamoylcystamine (CNCC), undergoes an extensive metabolism in the rat. Two pairs of plasma metabolites have been identified. This suggested our hypothesis that the metabolic pathway involves the reduction of the disulfur bridge followed by the methylation and the oxidation of the thiol groups. The two first intermediates, i.e. the unoxidized metabolites, could not be detected in vivo. Hence, to better understand and to confirm the proposed mechanism of biotransformation of CNCC, its in vitro metabolism has been studied. Incubation of CNCC with a rat liver homogenate or a 10,000g supernatant fraction leads to the formation of four pairs of metabolites. Among them we have identified the two first intermediates not found in vivo and the oxidized metabolites. These findings, together with the kinetics data, suggest that reduction, methylation, and oxidation are very rapid enzymatic reactions. We also show that, for completion of the reaction, the incubation mixture had to contain a cytosolic thioreductase, a microsomal and cytosolic S-methyltransferase, a microsomal oxidase, and an NADPH generating system. The sum of the amounts of metabolites found in the organic extratable material is less than the amount of CNCC metabolized. We conclude that the biotransformation of CNCC proceeds from two fast competitive mechanisms operative on both the disulfur and the nitroso groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868853

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  1 in total

1.  Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.

Authors:  Xavier Durando; Emilie Thivat; Michel D'Incan; Anne Sinsard; Jean-Claude Madelmont; Philippe Chollet
Journal:  BMC Cancer       Date:  2005-11-15       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.